ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein (HSIC) Extends Partnership With Special Olympics
by Zacks Equity Research
Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.
Zacks.com featured highlights BellRing Brands, ResMed, NVIDIA and Transdigm
by Zacks Equity Research
BellRing Brands, ResMed, NVIDIA and Transdigm have been highlighted in this Screen of The Week article.
Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
by Zacks Equity Research
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
4 Top Stocks to Invest in for Astounding Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.
QIAGEN (QGEN) to Enhance Forensics With New Partnership
by Zacks Equity Research
QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
by Zacks Equity Research
Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.
U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks
by Nalak Das
We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.
Teleflex (TFX) Expands Vascular Access Portfolio With New Launch
by Zacks Equity Research
Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
by Zacks Equity Research
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
by Zacks Equity Research
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Zacks.com featured highlights include ResMed, Booz Allen Hamilton and Kontoor Brands
by Zacks Equity Research
ResMed, Booz Allen Hamilton and Kontoor Brands have been highlighted in this Screen of The Week article.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
3 GARP Stocks to Scoop up for Maximum Returns
by Zacks Equity Research
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.